All About Multiple Sclerosis

More MS news articles for May 2004

Long-term effect of IFN-beta 1a therapy on CCL2 (MCP-1) chemokine in patients with multiple sclerosis

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15119740

Folia Neuropathol. 2004;42(1):15-8
Szczucinski A, Losy J.
Karol Marcinkowski's University School of Medicine, Poznan, Poland.

Chemokines play an important role in pathogenesis of multiple sclerosis (MS), mediating migration of leukocytes into the central nervous system.

CCL2 (MCP-1) chemokine is expressed in astrocytes in MS lesions.

The aim of the study was to evaluate the effect of a two-year treatment with IFN-beta 1a on serum CCL2 level in MS patients.

CCL2 concentration in sera of 18 relapsing-remitting MS (RR-MS) patients, and of 16 healthy controls was measured by ELISA.

MS patients were treated with interferon-beta 1a (Avonex) in a dose of 30 microg i.m. once weekly.

Significantly lower serum CCL2 level was found in MS patients in comparison with results of the control group.

CCL2 concentration increased significantly after one year of therapy with IFN-beta, and remained high after the two-year treatment.

The therapy of relapsing-remitting MS patients with interferon beta 1a is associated with a significant increase in CCL2 serum concentration.